 Denise Damek
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 21 | 2022 | 984 | 2.000 |
Why?
| | Glioblastoma | 11 | 2019 | 253 | 1.140 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 87 | 1.100 |
Why?
| | Astrocytoma | 5 | 2014 | 108 | 1.040 |
Why?
| | Meningioma | 4 | 2022 | 77 | 0.600 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2022 | 863 | 0.530 |
Why?
| | Chemoradiotherapy | 5 | 2015 | 190 | 0.500 |
Why?
| | Meningeal Carcinomatosis | 2 | 2014 | 8 | 0.450 |
Why?
| | Dacarbazine | 8 | 2016 | 101 | 0.430 |
Why?
| | Radiotherapy, Intensity-Modulated | 4 | 2015 | 125 | 0.410 |
Why?
| | Angiogenesis Inhibitors | 2 | 2014 | 215 | 0.390 |
Why?
| | Glioma | 4 | 2020 | 294 | 0.390 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2012 | 193 | 0.360 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2016 | 68 | 0.350 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.320 |
Why?
| | Quadriplegia | 1 | 2008 | 12 | 0.320 |
Why?
| | Aspergillus | 1 | 2008 | 16 | 0.320 |
Why?
| | Brain Abscess | 1 | 2008 | 11 | 0.320 |
Why?
| | Spinal Cord Diseases | 1 | 2008 | 38 | 0.320 |
Why?
| | Neck | 1 | 2008 | 83 | 0.310 |
Why?
| | Brain Diseases | 1 | 2009 | 124 | 0.300 |
Why?
| | Posture | 1 | 2008 | 153 | 0.300 |
Why?
| | Bevacizumab | 5 | 2020 | 115 | 0.290 |
Why?
| | Mutation | 3 | 2022 | 3350 | 0.270 |
Why?
| | Range of Motion, Articular | 1 | 2008 | 351 | 0.270 |
Why?
| | Middle Aged | 24 | 2020 | 26757 | 0.230 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1270 | 0.220 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 973 | 0.200 |
Why?
| | Flucytosine | 1 | 2020 | 9 | 0.180 |
Why?
| | Seizures | 2 | 2017 | 339 | 0.180 |
Why?
| | Cytosine Deaminase | 1 | 2020 | 14 | 0.180 |
Why?
| | Radiosurgery | 3 | 2010 | 302 | 0.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1361 | 0.180 |
Why?
| | Lymphoma | 3 | 2008 | 177 | 0.180 |
Why?
| | Multiple Sclerosis | 2 | 2012 | 380 | 0.170 |
Why?
| | Quinazolines | 3 | 2014 | 243 | 0.170 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 1895 | 0.160 |
Why?
| | Central Nervous System Neoplasms | 3 | 2008 | 126 | 0.160 |
Why?
| | Female | 25 | 2020 | 59507 | 0.160 |
Why?
| | Neurologic Examination | 1 | 2019 | 114 | 0.160 |
Why?
| | Emergency Service, Hospital | 1 | 2009 | 1812 | 0.160 |
Why?
| | Brain | 2 | 2009 | 2374 | 0.150 |
Why?
| | Adenocarcinoma | 1 | 2004 | 801 | 0.150 |
Why?
| | Humans | 33 | 2022 | 114757 | 0.150 |
Why?
| | Aged | 18 | 2020 | 19094 | 0.150 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2199 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2014 | 664 | 0.150 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2020 | 38 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 7 | 2016 | 3039 | 0.140 |
Why?
| | Brain Edema | 2 | 2009 | 60 | 0.140 |
Why?
| | Magnetic Field Therapy | 1 | 2016 | 2 | 0.140 |
Why?
| | Prognosis | 5 | 2015 | 3334 | 0.140 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 152 | 0.130 |
Why?
| | Survival Rate | 4 | 2015 | 1642 | 0.130 |
Why?
| | Neoplasms | 1 | 2009 | 2105 | 0.130 |
Why?
| | Male | 23 | 2020 | 55579 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2014 | 182 | 0.120 |
Why?
| | Oligodendroglioma | 1 | 2014 | 15 | 0.120 |
Why?
| | Adult | 17 | 2017 | 30548 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2539 | 0.120 |
Why?
| | Combined Modality Therapy | 5 | 2016 | 1122 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2016 | 4420 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 1997 | 429 | 0.110 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 195 | 0.100 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2015 | 333 | 0.100 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 373 | 0.090 |
Why?
| | Carcinoma | 1 | 2012 | 198 | 0.090 |
Why?
| | ErbB Receptors | 1 | 2014 | 560 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 994 | 0.080 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2009 | 9 | 0.080 |
Why?
| | Autopsy | 1 | 2009 | 84 | 0.080 |
Why?
| | Piperidines | 1 | 2010 | 161 | 0.080 |
Why?
| | Chloral Hydrate | 1 | 2008 | 3 | 0.080 |
Why?
| | Prospective Studies | 7 | 2015 | 6217 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2008 | 22 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2008 | 17 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1393 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2012 | 447 | 0.080 |
Why?
| | Oxycodone | 1 | 2008 | 44 | 0.080 |
Why?
| | Delirium | 1 | 2009 | 66 | 0.080 |
Why?
| | Drug Combinations | 1 | 2008 | 286 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 72 | 0.070 |
Why?
| | Hypnotics and Sedatives | 1 | 2008 | 134 | 0.070 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2008 | 117 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 275 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2017 | 2127 | 0.070 |
Why?
| | Antipsychotic Agents | 1 | 2008 | 184 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2008 | 328 | 0.070 |
Why?
| | Tumor Burden | 3 | 2012 | 261 | 0.070 |
Why?
| | Acetaminophen | 1 | 2008 | 238 | 0.070 |
Why?
| | Young Adult | 4 | 2017 | 10463 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 184 | 0.060 |
Why?
| | Occipital Lobe | 1 | 2004 | 23 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1340 | 0.060 |
Why?
| | Drug Overdose | 1 | 2008 | 292 | 0.060 |
Why?
| | Time Factors | 3 | 2010 | 6124 | 0.060 |
Why?
| | Radiotherapy | 1 | 2004 | 176 | 0.060 |
Why?
| | Methotrexate | 2 | 2008 | 227 | 0.060 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 17 | 0.060 |
Why?
| | Neoplasm Staging | 3 | 2015 | 1176 | 0.050 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2003 | 20 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2022 | 12515 | 0.050 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 27 | 0.050 |
Why?
| | Quality of Life | 1 | 2013 | 2358 | 0.050 |
Why?
| | Adolescent | 4 | 2017 | 17808 | 0.050 |
Why?
| | Dementia | 1 | 2005 | 187 | 0.050 |
Why?
| | Karnofsky Performance Status | 2 | 2013 | 36 | 0.050 |
Why?
| | Transferases | 1 | 2022 | 28 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2020 | 9089 | 0.050 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 718 | 0.050 |
Why?
| | Lomustine | 1 | 2020 | 14 | 0.050 |
Why?
| | Stroke | 1 | 2009 | 1019 | 0.050 |
Why?
| | Survival Analysis | 2 | 2020 | 1218 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 62 | 0.040 |
Why?
| | Radiotherapy Dosage | 2 | 2010 | 245 | 0.040 |
Why?
| | Dexamethasone | 2 | 2012 | 317 | 0.040 |
Why?
| | Reoperation | 2 | 2012 | 514 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 1999 | 82 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1040 | 0.040 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1999 | 71 | 0.040 |
Why?
| | Aged, 80 and over | 5 | 2010 | 6350 | 0.040 |
Why?
| | DNA Methylation | 1 | 2022 | 496 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1233 | 0.040 |
Why?
| | Intraoperative Complications | 1 | 2017 | 121 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1997 | 316 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2014 | 477 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2014 | 1226 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 178 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1351 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 926 | 0.030 |
Why?
| | Acute Disease | 1 | 1997 | 912 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 41 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2014 | 65 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 196 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2014 | 167 | 0.030 |
Why?
| | Sex Factors | 2 | 2014 | 1717 | 0.030 |
Why?
| | Exons | 1 | 2014 | 303 | 0.030 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2005 | 98 | 0.030 |
Why?
| | Proportional Hazards Models | 2 | 2010 | 1080 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2387 | 0.020 |
Why?
| | Chronic Disease | 1 | 1997 | 1590 | 0.020 |
Why?
| | Age Factors | 2 | 2014 | 2890 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 140 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 372 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 1997 | 2386 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 67 | 0.020 |
Why?
| | Carmustine | 1 | 2010 | 47 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 100 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3005 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 135 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 98 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2010 | 104 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1846 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 210 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 127 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1468 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 17 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 28 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 450 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2008 | 72 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 92 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 795 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 82 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 731 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 2973 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 770 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 33 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 150 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 1997 | 4409 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 532 | 0.020 |
Why?
| | Cognition | 1 | 2013 | 989 | 0.020 |
Why?
| | Pregnancy | 1 | 1997 | 5525 | 0.020 |
Why?
| | Dementia, Vascular | 1 | 2005 | 16 | 0.020 |
Why?
| | Optic Nerve | 1 | 2005 | 65 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 647 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2005 | 284 | 0.010 |
Why?
| | Lymphoma, B-Cell | 1 | 2005 | 86 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2099 | 0.010 |
Why?
| | Astrocytes | 1 | 2005 | 162 | 0.010 |
Why?
| | Child | 1 | 2022 | 18352 | 0.010 |
Why?
| | Microglia | 1 | 2005 | 202 | 0.010 |
Why?
| | United States | 2 | 2014 | 12176 | 0.010 |
Why?
| | Spinal Cord | 1 | 2005 | 347 | 0.010 |
Why?
| | Colorado | 1 | 2010 | 4086 | 0.010 |
Why?
| | Cohort Studies | 1 | 2010 | 4901 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 1999 | 21 | 0.010 |
Why?
| | Remission Induction | 1 | 1999 | 233 | 0.010 |
Why?
| | Databases as Topic | 1 | 1998 | 63 | 0.010 |
Why?
| | Animals | 1 | 1997 | 31762 | 0.010 |
Why?
| | Forecasting | 1 | 1998 | 331 | 0.010 |
Why?
| | Activities of Daily Living | 1 | 1998 | 350 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1998 | 1435 | 0.010 |
Why?
| | Hospitals | 1 | 1998 | 580 | 0.010 |
Why?
| | Logistic Models | 1 | 1998 | 1843 | 0.010 |
Why?
| | Registries | 1 | 1998 | 1759 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 1999 | 4625 | 0.000 |
Why?
| | Risk Factors | 1 | 1998 | 8627 | 0.000 |
Why?
|
|
Damek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|